Cosmos Health (NASDAQ:COSM) CEO Grigorios Siokas Acquires 766,284 Shares

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 766,284 shares of Cosmos Health stock in a transaction on Wednesday, July 29th. The shares were bought at an average price of $0.18 per share, with a total value of $137,931.12. Following the completion of the transaction, the chief executive officer directly owned 14,248,092 shares of the company’s stock, valued at $2,564,656.56. This trade represents a 5.68% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Thursday, June 11th, Grigorios Siokas acquired 218,447 shares of Cosmos Health stock. The shares were bought at an average cost of $0.21 per share, for a total transaction of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas bought 701,447 shares of Cosmos Health stock. The stock was bought at an average price of $0.23 per share, for a total transaction of $161,332.81.

Cosmos Health Stock Up 9.5%

Shares of NASDAQ COSM opened at $0.20 on Friday. The firm has a market cap of $12.01 million, a price-to-earnings ratio of -0.31 and a beta of 4.83. The company’s 50-day simple moving average is $0.23 and its 200-day simple moving average is $0.33. The company has a quick ratio of 0.92, a current ratio of 1.08 and a debt-to-equity ratio of 0.31. Cosmos Health Inc. has a 52-week low of $0.16 and a 52-week high of $1.32.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. The firm had revenue of $18.40 million during the quarter, compared to the consensus estimate of $17.93 million. Equities analysts predict that Cosmos Health Inc. will post 0.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Cosmos Health

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its position in Cosmos Health by 260.5% during the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock worth $167,000 after acquiring an additional 241,775 shares during the last quarter. Citadel Advisors LLC raised its holdings in Cosmos Health by 133.1% in the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after acquiring an additional 128,776 shares during the last quarter. Finally, XTX Topco Ltd raised its holdings in Cosmos Health by 52.1% in the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after acquiring an additional 34,117 shares during the last quarter. 12.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cosmos Health in a research report on Monday, June 15th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.